Evidence map›Paper›PMID 32963158›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy.

Sakue Masuda, Kazuya Koizumi, Hidekazu Moriya, Takashi Nishino, Haruki Uojima, Tomohiko Tazawa, Karen Kimura, Junichi Tasaki, Chikamasa Ichita, Akiko Sasaki and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Sakue MasudaDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Kazuya KoizumiDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Hidekazu MoriyaDepartment of Nephrology, Shonan Kamakura General Hospital, Japan.
Takashi NishinoDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Haruki UojimaDepartment of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Japan.
Tomohiko TazawaDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Karen KimuraDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Junichi TasakiDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Chikamasa IchitaDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Akiko SasakiDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Makoto KakoDepartment of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.
Sumi HidakaDepartment of Nephrology, Shonan Kamakura General Hospital, Japan.
Madoka KudoDepartment of Pathology, Shonan Kamakura General Hospital, Japan.
Shonan Kamakura General Hospital · JPKitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein describe an 82-year-old patient who presented with proteinuria and systemic edema. He was diagnosed with minimal change disease (MCD) and was found to have stage III pancreatic cancer. He could not undergo surgical resection due to invasion to the celiac artery and he was thus treated with chemotherapy. After a month of chemotherapy, his proteinuria improved to a normal level. After two months of chemotherapy, computed tomography indicated a partial response to the therapy. MCD can occur as paraneoplastic syndrome in patients with malignant disease, and chemotherapy can be effective for MCD associated with paraneoplastic syndrome.

Indexed as

Nephrosis, LipoidPancreatic NeoplasmsAged, 80 and overAlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineHumansMalePaclitaxelAlbuminsDeoxycytidinePaclitaxelchemoradiotherapyminimal change diseasenab-Paclitaxelpancreatic cancerproteinuria

Identifiers

PMID32963158
PMCPMC7872799
OpenAlexW3087152190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.